keyword
MENU ▼
Read by QxMD icon Read
search

Noac Venous thromboembolism

keyword
https://read.qxmd.com/read/30719364/a-case-of-pregnancy-complicated-with-atiii-deficiency-in-a-patient-who-developed-severe-venous-thromboembolism-in-her-fourth-pregnancy-and-had-a-favourable-outcome-in-her-subsequent-pregnancy-with-careful-management-of-anticoagulation-therapy-including-edoxaban
#1
Mie Sakai, Jumpei Ogura, Koji Yamanoi, Takahiro Hirayama, Tsutomu Ohara, Haruka Suzuki, Yoshihide Inayama, Koji Yasumoto, Koh Suginami
Congenital ATIII deficiency is one of the congenital thrombophilia diseases that can cause severe venous thromboembolism (VTE) in pregnant patients. A 30-year-old female, 4 gravida and 2 para, came to the emergency department with a complaint of oedema and pain in the left lower leg at 11 weeks of gestation. An inferior vena cava thrombus and pulmonary embolism were found. Because VTE was very severe, artificial abortion was performed, and VTE disappeared rapidly. She maintained oral administration of edoxaban (NOAC) and got pregnant naturally fifty-five weeks later after the abortion...
2019: Case Reports in Obstetrics and Gynecology
https://read.qxmd.com/read/30614320/rivaroxaban-for-non-valvular-atrial-fibrillation-and-venous-thromboembolism-in-the-netherlands-a-real-world-data-based-cost-effectiveness-analysis
#2
Lisa Aniek de Jong, Judith J Gout-Zwart, Marina van den Bosch, Mike Koops, Maarten J Postma
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) have been included in international guidelines as important alternatives to vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE) and stroke prevention in non-valvular atrial fibrillation (NVAF). Meanwhile, in the Netherlands, NOACs are widely used next to VKAs. The objective of our study is to estimate the cost-effectiveness of treatment with rivaroxaban compared to VKAs in NVAF and VTE patients in the Netherlands, using data from international prospective observational phase IV studies...
January 7, 2019: Journal of Medical Economics
https://read.qxmd.com/read/30602410/oral-anticoagulation
#3
Ertunc Altiok, Nikolaus Marx
BACKGROUND: Much new evidence on oral anticoagulation has come to light in recent years. Non-vitamin-K-dependent oral anti- coagulants (NOAC) have been developed and have been introduced into clinical practice. In this review, we present the current state of the evidence on anticoagulation for various indications with vitamin K antagonists (VKA) and with NOAC. METHODS: This review is based on pertinent articles retrieved by a selective search in PubMed (search terms: anticoagulation, atrial fibrillation, prosthetic valve, thrombosis, pulmonary embolism) and on specialty society recommendations and relevant guidelines from the years 2000-2018...
November 16, 2018: Deutsches Ärzteblatt International
https://read.qxmd.com/read/30597497/the-non-vitamin-k-antagonist-oral-anticoagulants-in-heart-disease-section-v-special-situations
#4
Raffaele De Caterina, Walter Ageno, Giancarlo Agnelli, Noel C Chan, Hans-Christoph Diener, Elaine Hylek, Gary E Raskob, Deborah M Siegal, Freek W A Verheugt, Gregory Y H Lip, Jeffrey I Weitz
Non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban and rivaroxaban, which inhibit factor Xa. In large clinical trials comparing the NOACs with the vitamin K antagonist (VKA) warfarin, dabigatran, apixaban, rivaroxaban and edoxaban were at least as effective for stroke prevention in atrial fibrillation and for treatment of venous thromboembolism, but were associated with less intracranial bleeding. In addition, the NOACs are more convenient to administer than VKAs because they can be given in fixed doses without routine coagulation monitoring...
January 2019: Thrombosis and Haemostasis
https://read.qxmd.com/read/30585539/novel-oral-anticoagulants-in-peripheral-artery-disease-current-evidence
#5
A Koutsoumpelis, C Argyriou, K M Tasopoulou, E I Georgakarakos, G S Georgiadis
BACKGROUND: Peripheral artery disease is a common manifestation of systemic atherosclerosis which strongly correlates to cardiovascular morbidity and mortality. In addition, the progression of peripheral artery disease leads to an increased risk of limb loss. In order to reduce these events, the benchmark of treatment and research over the last years has been the antiplatelet therapy which aims at inhibition of platelet aggregation. Over the last years, new studies combining antiplatelet agents in different therapeutic schemes have been proven efficacious...
December 26, 2018: Current Pharmaceutical Design
https://read.qxmd.com/read/30566971/utility-of-a-nurse-led-pathway-for-patients-with-acute-venous-thromboembolism-discharged-on-rivaroxaban-a-prospective-cohort-study
#6
Ming Sheng Lim, Tishya Indran, Anita Cummins, Ashwini Bennett, Erica Wood, Susan Brown, Zoe McQuilten, Huyen Tran, Master Clin Epi, Noel C Chan, Sanjeev Chunilal
The highest risk of adverse events for patients with acute venous thromboembolism (VTE) is during the early anticoagulation period. However, no established model exists for early clinical monitoring of patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). The authors' aim was to evaluate the utility of a nurse-led pathway to minimize adverse events in acute VTE patients starting on rivaroxaban. The rivaroxaban VTE treatment pathway is a prospective cohort study of consecutive patients with objectively confirmed VTE between July 2015 and May 2017...
December 19, 2018: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/30521639/rapid-and-substantial-increases-in-anticoagulant-use-and-expenditure-in-australia-following-the-introduction-of-new-types-of-oral-anticoagulants
#7
Alice Morgan, Grace Joshy, Andrea Schaffer, Tracey-Lea Laba, Melisa Litchfield, Sallie Pearson, Emily Banks
OBJECTIVES: To quantify changes in anticoagulant use in Australia since the introduction of Non-vitamin K antagonist anticoagulants (NOACs) and to estimate government expenditure. DESIGN: Interrupted-time-series analysis quantifying anticoagulant dispensing, before and after first Pharmaceutical Benefits Scheme (PBS) NOAC listing in August 2009 for venous thromboembolism prevention; and expanded listing for stroke prevention in non-valvular atrial fibrillation (AF) in August 2013, up to June 2016...
2018: PloS One
https://read.qxmd.com/read/30516757/knowledge-gaps-in-patients-with-venous-thromboembolism-usefulness-of-a-new-questionnaire
#8
Małgorzata Konieczyńska, Piotr Bijak, Lien Desteghe, Hein Heidbuchel, Anetta Undas
INTRODUCTION Little is known about the current awareness of venous thromboembolism (VTE) and knowledge of thromboprophylaxis among patients receiving oral anticoagulation therapy (OAC). OBJECTIVES We sought to develop and evaluate the usefulness of the Jessa AF Knowledge Questionnaire (JAKQ) modified for VTE patients. PATIENTS AND METHODS Consecutive patients at least one month since the VTE event (n=273, mean [SD] age 51 [17] years; 52.7% women; 55.9% unprovoked event) were enrolled at the study. RESULTS The median percentage of correct responses was 64...
December 5, 2018: Polish Archives of Internal Medicine
https://read.qxmd.com/read/30512143/-the-role-of-noac-in-orthopaedic-surgery-pros-and-cons
#9
Malin Carling, Bengt Eriksson
The risk for venous thromboembolism (VTE) is high in orthopaedic surgery in the lower extremities and pelvis. New oral anticoagulants (NOAC) have been shown to be efficient and safe as thrombosis prophylaxis after hip and knee arthroplasty surgery. The increased use of NOAC as prophylaxis in atrial fibrillation patients causes new problems in acute and elective surgery.
December 4, 2018: Läkartidningen
https://read.qxmd.com/read/30512135/-noac-in-combination-with-platelet-antiaggregation-in-both-patients-with-coronary-and-peripheral-arterial-disease
#10
Anders Gottsäter
New oral anticoagulants (NOAC) have been introduced in Swedish health care as first line treatment of atrial fibrillation and venous thromboembolism. NOAC have also been studied in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease, and reduced doses will presumably emerge as routine treatment also in these conditions.
December 4, 2018: Läkartidningen
https://read.qxmd.com/read/30409498/a-review-of-the-efficacy-and-safety-profiles-of-the-novel-oral-anticoagulants-in-the-treatment-and-prevention-of-venous-thromboembolism
#11
REVIEW
Alexis A Coulis, William C Mackey
PURPOSE: This study aims to review the published literature concerning the use of novel oral anticoagulants (NOACs) in the treatment and prevention of venous thromboembolism (VTE) and to identify the appropriate niche for each NOAC by comparing their behaviors in Phase III and Phase IV clinical trial settings. METHODS: The ClinicalTrials.gov database was used to identify Phase III and postmarketing (Phase IV) randomized controlled trials concerning the efficacy and safety profiles of the oral NOACs (apixaban, dabigatran etexilate, exodaban, and rivaroxaban) for the treatment or prevention of VTE...
December 2018: Clinical Therapeutics
https://read.qxmd.com/read/30406915/assessment-of-non-vitamin-k-oral-anticoagulants-use-in-a-tertiary-care-center-in-the-usa-a-chart-review-of-909-patients
#12
Marwan Sheikh-Taha, Mary E Deeb
BACKGROUND: Non-vitamin K oral anticoagulants (NOACs) have emerged as an attractive alternative to vitamin K antagonists for various thromboembolic indications. However, prescribed NOAC doses are often inconsistent with drug labeling and prescribers might not consider the potential risks associated with concomitant use of other drugs, which can compromise NOACs' safety and effectiveness. METHODS: A retrospective chart review was conducted in a tertiary care center in USA over a 4-month period...
November 8, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30354416/non-vitamin-k-antagonist-oral-anticoagulants-for-mechanical-heart-valves
#13
Alberto Aimo, Robert P Giugliano, Raffaele De Caterina
The estimated prevalence of mitral or aortic valvular heart disease is ≈2.5% in the general population of Western countries, and is expected to rise with population aging. A substantial proportion of patients with valvular heart disease undergoes surgical valve replacement. Mechanical heart valves are much more durable than bioprostheses, and are thus preferentially implanted in patients with a longer life expectancy, but have the major drawback of requiring lifelong anticoagulation to prevent valve thrombosis because of their higher thrombogenicity...
September 25, 2018: Circulation
https://read.qxmd.com/read/30347966/dabigatran-the-first-approved-dti-for-spaf
#14
Abhijit Trailokya, J S Hiremath
Atrial fibrillation (AF) is commonly occurring arrhythmia in clinical practice. AF is easy to recognize but difficult to treat. Stroke is the most devastating complication of AF and is associated with a huge disease burden on the society. Effective stroke prevention is a priority for patients with AF. Two-thirds of strokes due to AF are preventable with suitable anticoagulant therapy. VKA like warfarin, acenocoumarol remains the gold standard for stroke prevention in AF (SPAF). However, it is associated with numerous limitations such as a high risk of drug-drug, drug-food interactions and need for frequent PT/INR monitoring...
April 2018: Journal of the Association of Physicians of India
https://read.qxmd.com/read/30277082/pharmacokinetics-of-new-oral-anticoagulants-implications-for-use-in-routine-care
#15
REVIEW
Ylenia Ingrasciotta, Salvatore Crisafulli, Valeria Pizzimenti, Ilaria Marcianò, Anna Mancuso, Giuseppe Andò, Salvatore Corrao, Piera Capranzano, Gianluca Trifirò
Since 2008, new oral anticoagulants (NOACs) have been approved for the prevention of venous thromboembolism (VTE) in patients receiving hip or knee replacement surgery, prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE). Premarketing randomized clinical trials (RCTs) of NOACs demonstrated their non-inferiority in terms of efficacy vs. warfarin (traditional oral anticoagulant - TOA), with lower risk of serious adverse drug reactions, especially cerebral hemorrhages...
October 2018: Expert Opinion on Drug Metabolism & Toxicology
https://read.qxmd.com/read/30270775/bleeding-in-patients-receiving-non-vitamin-k-oral-anticoagulants-clinical-trial-evidence
#16
Arthur Bracey, Wassim Shatila, James Wilson
In optimizing anticoagulation therapy, it is essential to balance treatment efficacy with the major adverse effect of anticoagulant treatment, bleeding risk. This narrative review examines the efficacy and safety of the non-vitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, and edoxaban compared with standard anticoagulation or placebo. NOAC therapies provide equivalent to superior protection versus standard therapy, with similar or superior safety, and potential benefits in convenience...
December 2018: Therapeutic Advances in Cardiovascular Disease
https://read.qxmd.com/read/30100750/the-impact-of-abcb1-rs1045642-and-rs4148738-and-ces1-rs2244613-gene-polymorphisms-on-dabigatran-equilibrium-peak-concentration-in-patients-after-total-knee-arthroplasty
#17
Dmitriy Alekseevich Sychev, Alexander Nikolaevich Levanov, Tatiana Vladimirovna Shelekhova, Pavel Olegovich Bochkov, Natalia Pavlovna Denisenko, Kristina Anatolyevna Ryzhikova, Karin Badavievich Mirzaev, Elena Anatolyevna Grishina, Mikhail Alekseevich Gavrilov, Galina Vladislavovna Ramenskaya, Aleksei Vladimirovich Kozlov, Tanya Bogoslovsky
Background: Non-vitamin K oral anticoagulants (NOACs) are commonly used for prophylaxis of venous thromboembolism (VTE) in orthopedic patients. Despite known safety and high potency of NOACs, potential interactions of NOACs with genetic polymorphisms are poorly understood. Dabigatran etexilate is one of the most commonly prescribed direct thrombin inhibitors for the prevention of VTE. The objectives of this study were to assess the effect of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) polymorphisms on dabigatran pharmacokinetics in patients after total knee arthroplasty...
2018: Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/30067518/betrixaban-a-novel-factor-xa-inhibitor-for-the-prevention-of-venous-thromboembolism-in-acutely-ill-medical-patients
#18
REVIEW
Katie Lee, Samantha Cham, Sum Lam
Venous thromboembolism (VTE) is a common and preventable cause of morbidity and mortality in hospitalized patients. Low-molecular-weight heparin, low-dose unfractionated heparin, fondaparinux, and warfarin have been the mainstay options for the prevention and treatment of VTE before the emergence of nonvitamin K antagonist oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban. Despite the advantages of NOACs in improving patient adherence, none of them are approved for the prevention of VTE in acutely ill medical patients at high risk of thromboembolism...
November 2018: Cardiology in Review
https://read.qxmd.com/read/29976282/a-literature-review-of-antithrombotic-therapy-for-patients-of-venous-thromboembolic-events-with-comorbidity-of-coronary-heart-disease
#19
Meng-Xin Zhou, Rui Sun, Yue-Xin Chen
Patients with venous thromboembolism (VTE) and concurrent coronary heart disease (CHD) are not rare in clinic. The main challenge in the treatment for these patients is that the antithrombotic therapies for VTE and CHD are different from each other, but the combination of the two therapeutic strategies would increase the risk of bleeding. There is a need to optimize the antithrombotic therapeutic scheme on the basis of individual conditional, in order to balance the therapeutic effects and the bleeding risk...
June 30, 2018: Chinese Medical Sciences Journal, Chung-kuo i Hsüeh K'o Hsüeh Tsa Chih
https://read.qxmd.com/read/29973997/newer-oral-anticoagulants-in-the-treatment-of-acute-portal-vein-thrombosis-in-patients-with-and-without-cirrhosis
#20
REVIEW
P Priyanka, J T Kupec, M Krafft, N A Shah, G J Reynolds
Background: Newer oral anticoagulants (NOACs) are being utilized increasingly for the treatment of venous thromboembolism (VTE). NOAC use is the standard of care for stroke prophylaxis in nonvalvular atrial fibrillation and treatment of acute VTE involving extremities and pulmonary embolism. In contrast, most guidelines in the literature support the treatment of acute portal vein thrombosis (PVT) with low molecular weight heparin (LMWH) and vitamin K antagonists (VKA). Literature evaluating NOAC use in the treatment of acute portal vein thrombosis is sparse...
2018: International Journal of Hepatology
keyword
keyword
166493
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"